Literature DB >> 17628496

Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.

N Sahara1, S Maeda, Y Yoshiike, T Mizoroki, S Yamashita, M Murayama, J-M Park, Y Saito, S Murayama, A Takashima.   

Abstract

Intracellular accumulation of filamentous tau proteins is a defining feature of neurodegenerative diseases termed tauopathies. The pathogenesis of tauopathies remains largely unknown. Molecular chaperones such as heat shock proteins (HSPs), however, have been implicated in tauopathies as well as in other neurodegenerative diseases characterized by the accumulation of insoluble protein aggregates. To search for in vivo evidence of chaperone-related tau protein metabolism, we analyzed human brains with varying degrees of neurofibrillary tangle (NFT) pathology, as defined by Braak NFT staging. Quantitative analysis of soluble protein levels revealed significant positive correlations between tau and Hsp90, Hsp40, Hsp27, alpha-crystallin, and CHIP. An inverse correlation was observed between the levels of HSPs in each specimen and the levels of granular tau oligomers, the latter of which were isolated from brain as intermediates of tau filaments. We speculate that HSPs function as regulators of soluble tau protein levels, and, once the capacity of this chaperone system is saturated, granular tau oligomers form virtually unabated. This is expressed pathologically as an early sign of NFT formation. The molecular basis of chaperone-mediated protection against neurodegeneration might lead to the development of therapeutics for tauopathies. (c) 2007 Wiley-Liss, Inc. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628496     DOI: 10.1002/jnr.21417

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  43 in total

1.  Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response.

Authors:  David B Wang; Robert D Dayton; Richard M Zweig; Ronald L Klein
Journal:  Exp Neurol       Date:  2010-03-24       Impact factor: 5.330

2.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

4.  Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.

Authors:  Binnur Eroglu; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

Review 5.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 6.  Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases.

Authors:  Herman van der Putten; Gregor P Lotz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.

Authors:  Shannon N Campbell; Cheng Zhang; Louise Monte; Allyson D Roe; Kenner C Rice; Yvette Taché; Eliezer Masliah; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 8.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 9.  The role of amyloidogenic protein oligomerization in neurodegenerative disease.

Authors:  Gregor P Lotz; Justin Legleiter
Journal:  J Mol Med (Berl)       Date:  2013-03-27       Impact factor: 4.599

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.